The DOI matches its Crossref record.
A potentially hazardous interaction between erythromycin and midazolam
Abstract
Interaction between erythromycin and midazolam was investigated in two double-blind, randomized, crossover studies. In the first study, 12 healthy volunteers were given 500 mg erythromycin three times a day or placebo for 1 week. On the sixth day, the subjects ingested 15 mg midazolam. In the second study, midazolam (0.05 mg/kg) was given intravenously to six of the same subjects, after similar pretreatments. Plasma samples were collected, and psychomotor performance was measured. Erythromycin increased the area under the midazolam concentration-time curve after oral intake more than four times (p < 0.001) and reduced clearance of intravenously administered midazolam by 54% (p < 0.05). In psychomotor tests (e.g., saccadic eye movements), the interaction between erythromycin and orally administered midazolam was statistically significant (p < 0.05) from 15 minutes to 6 hours. Metabolism of both erythromycin and midazolam by the same cytochrome P450IIIA isozyme may explain the observed pharmacokinetic interaction. Prescription of midazolam for patients receiving erythromycin should be avoided or the dose of midazolam should be reduced by 50% to 75%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Coté, C. J., Wilson, S., AMERICAN ACADEMY OF PEDIATRICS, & AMERICAN ACADEMY OF PEDIATRIC DENTISTRY (2019) · Pediatrics · doi:10.1542/peds.2019-1000 · Cited by 1,406
Cytochrome P450 Enzymes and Drug Metabolism in Humans
Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., He, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312808 · Cited by 1,070
Dresser, G. K., Spence, J. D., & Bailey, D. G. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038010-00003 · Cited by 908
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831
Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.815 · Cited by 792
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Thummel, K. E., O'Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., & Wilkinson, G. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90177-0 · Cited by 617
Adverse Sedation Events in Pediatrics: Analysis of Medications Used for Sedation
Coté, C. J., Karl, H. W., Notterman, D. A., Weinberg, J. A., & McCloskey, C. (2000) · Pediatrics · doi:10.1542/peds.106.4.633 · Cited by 616
American Academy of Pediatrics, American Academy of Pediatric Dentistry, Coté, C. J., Wilson, S., & the Work Group on Sedation (2006) · Pediatrics · doi:10.1542/peds.2006-2780 · Cited by 555
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs
Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., & McLeod, H. L. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544030-00005 · Cited by 517
Midazolam and Other Benzodiazepines
Olkkola, K. T., & Ahonen, J. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-74806-9_16 · Cited by 488
Self-citationStreetman, D. S., Bertino, J. S., & Nafziger, A. N. (2000) · Pharmacogenetics · doi:10.1097/00008571-200004000-00001 · Cited by 425
Gorski, J. C., Jones, D. R., Haehner-Daniels, B. D., Hamman, M. A., O'Mara, E. M., & Hall, S. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90146-1 · Cited by 411
Preskorn, S. H. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199700321-00003 · Cited by 370
Interaction between grapefruit juice and midazolam in humans*
Kupferschmidt, H. H. T., Ha, H. R., Ziegler, W. H., Meier, P. J., & Krähenbühl, S. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90068-3 · Cited by 359
Inhibition and induction of human cytochrome P450 (CYP) enzymes
PELKONEN, O., MÄEENPÄEÄ, J., TAAVITSAINEN, P., RAUTIO, A., & RAUNIO, H. (1998) · Xenobiotica · doi:10.1080/004982598238886 · Cited by 358
Kivisto, K., Kroemer, H., & Eichelbaum, M. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05796.x · Cited by 340
Cytochrome P450-mediated metabolism in the human gut wall
Thelen, K., & Dressman, J. B. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.05.0002 · Cited by 338
Midazolam: A review of therapeutic uses and toxicity
Nordt, S. P., & Clark, R. F. (1997) · The Journal of Emergency Medicine · doi:10.1016/s0736-4679(97)00022-x · Cited by 337
The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective
Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., et al. (2003) · Journal of Clinical Pharmacology · doi:10.1177/0091270003043005001 · Cited by 315
Update on Bispectral Index monitoring
Johansen, J. W. (2006) · Best Practice & Research Clinical Anaesthesiology · doi:10.1016/j.bpa.2005.08.004 · Cited by 313
Clinical Pharmacology of Midazolam in Infants and Children
Blumer, J. L. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835010-00003 · Cited by 313
Effect of itraconazole on the pharmacokinetics of atorvastatin*
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90023-6 · Cited by 300
Self-citationMayhew, B. S., Jones, D. R., & Hall, S. D. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15182-3 · Cited by 293
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90151-5 · Cited by 286
Self-citationDifferential Induction of Prehepatic and Hepatic Metabolism of Verapamil by Rifampin
Fromm, M. F., Busse, D., Kroemer, H. K., & Eichelbaum, M. (1996) · Hepatology · doi:10.1002/hep.510240407 · Cited by 283
Yuan, R., Flockhart, D. A., & Balian, J. D. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/009127009903901102 · Cited by 271
Coté, C. J., Wilson, S., AMERICAN ACADEMY OF PEDIATRICS, & AMERICAN ACADEMY OF PEDIATRIC DENTISTRY (2016) · Pediatrics · doi:10.1542/peds.2016-1212 · Cited by 260
Romero, L. M., & Remage-Healey, L. (2000) · General and Comparative Endocrinology · doi:10.1006/gcen.2000.7491 · Cited by 259
Barry, M., Gibbons, S., Back, D., & Mulcahy, F. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00003 · Cited by 254
Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
Neuvonen, P. J., & Jalava, K.-M. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90167-8 · Cited by 238
Self-citationDrug interactions in dentistry
HERSH, E. V., & MOORE, P. A. (2004) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2004.0178 · Cited by 78
Heikkinen, A. T., Baneyx, G., Caruso, A., & Parrott, N. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.06.013 · Cited by 76
Bolhuis, M. S., Panday, P. N., Pranger, A. D., Kosterink, J. G. W., & Alffenaar, J.-W. C. (2011) · Pharmaceutics · doi:10.3390/pharmaceutics3040865 · Cited by 62
(2001) · Indian Journal of Pharmacology · Cited by 52
Clinically significant pharmacokinetic drug interactions with benzodiazepines
Tanaka, E. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00247.x · Cited by 52
Metadata
- Authors
- Olkkola, K. T., Aranko, K., Luurila, H., Hiller, A., Saarnivaara, L., Himberg, J.-J., & Neuvonen, P. J.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1993-03
- Volume
- 53
- Issue
- 3
- Pages
- 298-305
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2104093795
- Cited by
- 351
- References
- 0
- FWCI
- 18.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.